Tumor mutational burden as a prognostic biomarker for survival and quality of life in metastatic colorectal cancer patients receiving anti-PD-1/PD-L1 immunotherapy: A retrospective cohort study.

Abstract excerpt

The aim of this study was to assess the prognostic value of tumor mutational burden (TMB) as a biomarker for metastatic colorectal cancer (mCRC) in patients receiving immunotherapy-containing regimens. This retrospective cohort study analyzed 221 patients with mCRC. From January 1, 2020 to December 31, 2021, patients diagnosed with unresectable mCRC at the time of initial diagnosis were screened and stratified...

Topics

• Humans
• Colorectal Neoplasms
• Retrospective Studies
• Quality of Life
• Female
• Male